Özge ASLAN, Ayşenur OKTAY, Levent YENİAY

Neoadjuvan kemoterapinin olası benign meme lezyonları üzerindeki etkilerinin MRG ile değerlendirilmesi: İki olgu sunumu

Meme kanseri olgularında memenin diğer bölgelerinde de olası benign lezyonlar görülebilir. Neoadjuvan kemoterapinin malign kitle üzerindeki etkilerinin yanı sıra normal meme dokusunda ve benign lezyonlarda morfolojik değişikliklere neden olduğu bilinmektedir. Neoadjuvan kemoterapi ile tam yanıt alınan olgularda, tedavi öncesi doku tanısı konulmamış olası benign lezyonlar tedavi sonunda küçüldüğünde veya kaybolduğunda meme koruyucu cerrahi planında ikilem yaratmaktadır. Bu olgu sunumunda olası benign meme lezyonu olan iki olguda neoadjuvan kemoterapinin etkilerini dinamik kontrastlı meme MRG ile göstermeyi amaçladık.

Evaluation of the effects of neoadjuvant chemotherapy on probably benign breast lesions with MRI: Report of two cases

In cases with breast cancer, probably benign lesions can also be seen in the other areas of the breast. It is known that neoadjuvant chemotherapy causes morphological changes in the normal breast tissue and the benign lesions, in addition to effects on malignant mass. In cases with complete response with neoadjuvant chemotherapy, probably benign lesions without tissue diagnosis cause a dilemma in the breast conserving surgery plan, when they shrink or disappear at the end of the treatment. We aimed to demonstrate the effects of neoadjuvant chemotherapy in cases with probably benign breast lesions via dynamic contrast enhanced breast MRI.

PDF

___

1. Panigrahi B, Harvey SC, Mullen LA, et al. Characteristics and Outcomes of BI-RADS 3 Lesions on Breast MRI. Clin Breast Cancer. 2019 Feb; 19 (1): e152-e159.
2. Schott AF, Roubidoux MA, Helvie MA, et al. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2005 Aug; 92 (3): 231-8.
3. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007 Oct 1; 25 (28): 4414-22.
4. Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res. 2008 Oct 15; 14 (20): 6580-9.
5. Carder P. Typing breast cancer following primary chemotherapy. Histopathology. 1999 Dec; 35 (6): 584-5.
6. Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol. 2005 Mar; 184 (3): 868-77.
7. Leddy R, Irshad A, Hewett L, et al. Effects of neoadjuvant chemotherapy on benign breast lesions compared to cancers: Should an additional lesion on magnetic resonance imaging responding similar to cancer after neoadjuvant chemotherapy be viewed with suspicion? J Clin Imaging Sci. 2016 Sep 20; 6: 39.
8. Gu YL, Pan SM, Ren J, Yang ZX, Jiang GQ. Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Meta-analysis. Clin Breast Cancer. 2017 Jul; 17 (4): 245-55.
9. Spick C, Bickel H, Polanec SH, Baltzer PA. Breast lesions classified as probably benign (BI-RADS 3) on magnetic resonance imaging: a systematic review and meta-analysis. Eur Radiol. 2018 May; 28 (5): 1919-28.
10. Moll UM, Chumas J. Morphologic effects of neoadjuvant chemotherapy in locally advanced breast cancer. Pathol Res Pract. 1997; 193 (3): 187-96.